Derek S Tsang1, Erin S Murphy2, Thomas E Merchant3. 1. Department of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. 2. Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio. 3. Department of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. Electronic address: thomas.merchant@stjude.org.
Abstract
PURPOSE: The long-term survival of pediatric patients with optic pathway or hypothalamic low-grade glioma (LGG) who receive radiation therapy (RT) has not been previously assessed. METHODS AND MATERIALS: A retrospective study was performed of all patients with optic-hypothalamic pediatric LGG treated with RT at a single institution. Eligible patients were aged ≤21 years at the time of RT and had localized LGG diagnosed by neuroimaging or histology. The median RT dose was 54 Gy, delivered in 30 fractions. Event-free survival (EFS) was defined as survival without progression or secondary high-grade glioma. Days were counted from the first day of RT. RESULTS: Eighty-nine patients were included in the study, with a median follow-up period of 12.5 years. Of the patients, 14 had neurofibromatosis type 1 (NF-1). The 10-year EFS rate was 61.9% (95% confidence interval [CI], 31.2%-82.1%) for patients with NF-1 and 67.5% (95% CI, 54.8%-77.3%) for those without NF-1. The 10-year overall survival rate was 92.3% (95% CI, 56.6%-98.9%) for patients with NF-1 and 98.4% (95% CI, 89.1%-99.8%) for those without NF-1. Pre-RT chemotherapy (which was more commonly given to younger patients) was associated with reduced EFS, whereas younger age was associated with reduced overall survival. Possible RT-induced neoplasms developed in 8 patients, including 4 with NF-1. The 10-year cumulative incidence of clinically significant vasculopathy was 7.1% (95% CI, 2.9%-13.9%); vasculopathy did not develop in any child aged >10 years at the commencement of RT. CONCLUSIONS: RT is an effective treatment for optic-hypothalamic LGG. Older children without NF-1 have a low risk of late toxicity. RT can be considered for selected younger patients or individuals with NF-1 as a salvage treatment after progression.
PURPOSE: The long-term survival of pediatric patients with optic pathway or hypothalamic low-grade glioma (LGG) who receive radiation therapy (RT) has not been previously assessed. METHODS AND MATERIALS: A retrospective study was performed of all patients with optic-hypothalamic pediatric LGG treated with RT at a single institution. Eligible patients were aged ≤21 years at the time of RT and had localized LGG diagnosed by neuroimaging or histology. The median RT dose was 54 Gy, delivered in 30 fractions. Event-free survival (EFS) was defined as survival without progression or secondary high-grade glioma. Days were counted from the first day of RT. RESULTS: Eighty-nine patients were included in the study, with a median follow-up period of 12.5 years. Of the patients, 14 had neurofibromatosis type 1 (NF-1). The 10-year EFS rate was 61.9% (95% confidence interval [CI], 31.2%-82.1%) for patients with NF-1 and 67.5% (95% CI, 54.8%-77.3%) for those without NF-1. The 10-year overall survival rate was 92.3% (95% CI, 56.6%-98.9%) for patients with NF-1 and 98.4% (95% CI, 89.1%-99.8%) for those without NF-1. Pre-RT chemotherapy (which was more commonly given to younger patients) was associated with reduced EFS, whereas younger age was associated with reduced overall survival. Possible RT-induced neoplasms developed in 8 patients, including 4 with NF-1. The 10-year cumulative incidence of clinically significant vasculopathy was 7.1% (95% CI, 2.9%-13.9%); vasculopathy did not develop in any child aged >10 years at the commencement of RT. CONCLUSIONS: RT is an effective treatment for optic-hypothalamic LGG. Older children without NF-1 have a low risk of late toxicity. RT can be considered for selected younger patients or individuals with NF-1 as a salvage treatment after progression.
Authors: Sahaja Acharya; Jo-Fen Liu; Ruth G Tatevossian; Jason Chiang; Ibrahim Qaddoumi; Amar Gajjar; David Walker; Julie H Harreld; Thomas E Merchant; David W Ellison Journal: Neuro Oncol Date: 2020-08-17 Impact factor: 12.300
Authors: Sahaja Acharya; Sophia Quesada; Kenneth Coca; Cody Richardson; Mary E Hoehn; Jason Chiang; Ibrahim Qaddoumi; Frederick A Boop; Amar Gajjar; Thomas E Merchant Journal: J Neurooncol Date: 2019-08-14 Impact factor: 4.130
Authors: Kohei Fukuoka; Yasin Mamatjan; Ruth Tatevossian; Michal Zapotocky; Scott Ryall; Ana Guerreiro Stucklin; Julie Bennett; Liana Figueiredo Nobre; Anthony Arnoldo; Betty Luu; Ji Wen; Kaicen Zhu; Alberto Leon; Dax Torti; Trevor J Pugh; Lili-Naz Hazrati; Normand Laperriere; James Drake; James T Rutka; Peter Dirks; Abhaya V Kulkarni; Michael D Taylor; Ute Bartels; Annie Huang; Gelareh Zadeh; Kenneth Aldape; Vijay Ramaswamy; Eric Bouffet; Matija Snuderl; David Ellison; Cynthia Hawkins; Uri Tabori Journal: Neuro Oncol Date: 2020-10-14 Impact factor: 12.300
Authors: Ciaran Scott Hill; Mehdi Khan; Kim Phipps; Katherine Green; Darren Hargrave; Kristian Aquilina Journal: Childs Nerv Syst Date: 2021-02-03 Impact factor: 1.475
Authors: Ciaran Scott Hill; Sara Castro Devesa; William Ince; Anouk Borg; Kristian Aquilina Journal: Childs Nerv Syst Date: 2020-06-18 Impact factor: 1.475